-
Caspase-3 Drives Melanoma Motility via Coronin 1B
2026-09-11
The 2025 Cell Death and Disease study identifies a non-apoptotic function of caspase-3 in melanoma, showing that it regulates migration and invasion through coronin 1B and actin remodeling. These findings separate caspase-3 abundance from its conventional executioner role and provide a framework for studying apoptotic and metastatic phenotypes in parallel.
-
ARCA EGFP mRNA (5-moUTP) Workflow Guide
2026-09-11
Build a reproducible fluorescence-based transfection control around a polyadenylated mRNA reporter that measures functional delivery and protein expression directly. This workflow also shows how to use the reporter to benchmark lipid formulations while separating potency, cell health, and inflammation-related effects.
-
Measuring Drug Response Beyond Cell Viability
2026-09-10
Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these commonly conflated readouts capture different relationships between growth inhibition and cell death. The work provides a practical framework for interpreting in vitro cancer drug responses with greater temporal and biological resolution.
-
Myriocin Workflows for Sphingolipid Research
2026-09-10
Myriocin enables controlled inhibition of serine palmitoyltransferase for sphingolipid metabolism research, cancer research, and mechanistic metabolic studies. This practical guide connects stock handling, cell-based dose finding, metabolic phenotyping, and troubleshooting to findings from a 2025 mouse study.
-
Vancomycin Hydrochloride in Regenerative Assays
2026-09-09
Vancomycin hydrochloride can do more than serve as a routine antimicrobial control: it can help researchers separate Gram-positive contamination signals from tissue-engineering performance. This article connects its mechanism and handling requirements with assay decisions inspired by a large-animal engineered-esophagus study.
-
EZ Cap EGFP mRNA 5-moUTP Guide
2026-09-09
EZ Cap EGFP mRNA 5-moUTP is an enhanced green fluorescent protein mRNA designed for stable, reproducible reporter expression. Its Cap1 structure, 5-moUTP nucleotides, and optimized poly(A) tail support translation-focused assays while the cited LNP study illustrates how carrier design can change mRNA delivery outcomes.
-
EPZ-6438: From PRC2 Biology to Translation
2026-09-08
EZH2 inhibition is moving from a molecular concept toward a biomarker-led translational strategy. This thought-leadership article examines how EPZ-6438 connects SAM-pocket selectivity and H3K27me3 depletion with findings in EZH2-mutant lymphoma, malignant rhabdoid tumor, and HPV-associated cervical cancer. It also outlines a practical workflow for linking chromatin pharmacodynamics to phenotype while distinguishing preclinical promise from clinical evidence.
-
Reserpine (N1867): Lab Workflow Guide
2026-09-07
Reserpine (SKU N1867) provides a high-purity research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. It is intended only for laboratory use; it is not a diagnostic, therapeutic, veterinary, or clinical product, and no paper-specific efficacy or dose-response claims are made here.
-
ETS1–SENP2–HSPA8 Axis in Bronchopulmonary Dysplasia
2026-09-07
The reference study identifies ETS1 as a transcriptional regulator that limits mitochondrial damage-induced mitophagy in bronchopulmonary dysplasia through the SENP2/HSPA8/FUNDC1 pathway. Its findings connect SENP2-mediated deSUMOylation of FUNDC1 with HSPA8-dependent FUNDC1 turnover, providing a mechanistic framework for studying mitochondrial quality control in hyperoxic lung injury.
-
VER 155008: HSP 70 Inhibitor Workflow
2026-09-05
VER 155008 connects direct Hsp70 ATPase inhibition with practical apoptosis, viability, and proteomic assays. This workflow helps researchers distinguish target engagement from downstream cancer cell proliferation inhibition while highlighting formulation, exposure, and interpretation limits.
-
Butyrate, Lysosomal Iron, and Lung Cancer Stemness
2026-09-04
The reference study shows that butyrate suppresses lung cancer stemness through a ferroptotic mechanism involving lysosomal Fe2+ recruitment and reduced SLC7A11 protein stability. Its integrated sphere-formation, molecular, migration, chemotherapy-sensitivity, and tumorigenesis experiments provide a useful framework for connecting metabolic regulation with cancer stem cell vulnerability.
-
circEIF2S2 in Colorectal Cancer Progression
2026-09-04
The reference study identifies an EIF4A3–circEIF2S2–miR-646–UHMK1 regulatory axis that connects circular RNA biogenesis with colorectal cancer growth, metastasis, and immune suppression. Its combination of expression profiling, loss-of-function experiments, rescue studies, immune co-culture, and xenograft models provides a mechanistic framework for evaluating circEIF2S2 as a potential biomarker and therapeutic target.
-
Hsa_circ_0001944, FXR/TLR4, and NiONP Fibrosis
2026-09-04
A 2025 Toxics study identifies hsa_circ_0001944 as a regulatory link connecting FXR/TLR4 signaling, ferroptosis, and nickel oxide nanoparticle-induced collagen deposition in LX-2 hepatic stellate cells. Pharmacological perturbation and circRNA overexpression together provide a mechanistic framework for studying toxicant-associated liver fibrosis, while the cell-based design limits direct translation to human disease.
-
Triazole ALDH2 Activators in Myocardial Ischemia
2026-09-03
The reference study combines molecular simulation, triazole scaffold design, biochemical testing, and mouse ischemia–reperfusion experiments to identify Z17 as a highly active ALDH2 activator. Z17 improved cardiac function and reduced biochemical and histological indicators of myocardial injury, while its improved water solubility addresses a limitation of earlier ALDH2 activators.
-
JC-1 Mitochondrial Membrane Potential Assay Guide
2026-09-02
Turn JC-1 fluorescence into a practical readout of mitochondrial stress, apoptosis, and treatment response. This workflow emphasizes ratio-based analysis, CCCP controls, and application-specific optimization for cancer and mitochondrial research.